All Stories

  1. Selective use of sorafenib in the treatment of thyroid cancer

    Article • Drug Design Development and Therapy, March 2016, Dove Medical Press

    Fabian Pitoia

  2. Definition and management of radioactive iodine-refractory differentiated thyroid cancer

    Article • The Lancet Diabetes & Endocrinology, May 2014, Elsevier

    Fabian Pitoia

  3. Erratum to: Biochemical persistence in thyroid cancer: is there anything to worry about?

    Article • Endocrine, February 2014, Springer Science + Business Media

    Fabian Pitoia

  4. Response to sorafenib treatment in advanced metastatic thyroid cancer

    Article • Arquivos Brasileiros de Endocrinologia & Metabologia, February 2014, FapUNIFESP (SciELO)

    Fabian Pitoia

  5. Sorafenib: is a partial response and stabilization of disease greater than 70% a modest response?

    Article • January 2014, Bioscientifica

    Fabian Pitoia

  6. Biochemical persistence in thyroid cancer: is there anything to worry about?

    Article • Endocrine, November 2013, Springer Science + Business Media

    Fabian Pitoia

  7. Outcomes of Patients with Differentiated Thyroid Cancer Risk-Stratified According to the American Thyroid Association and Latin American Thyroid Society Risk of Recurrence Classification Systems

    Article • Thyroid, November 2013, Mary Ann Liebert Inc

    Fabian Pitoia

  8. Undetectable pre-ablation thyroglobulin levels in patients with differentiated thyroid cancer: it is not always what it seems

    Article • Arquivos Brasileiros de Endocrinologia & Metabologia, June 2013, FapUNIFESP (SciELO)

    Fabian Pitoia

  9. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions

    Article • Expert Review of Endocrinology & Metabolism, September 2012, Taylor & Francis

    Fabian Pitoia

  10. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma

    Article • Expert Review of Anticancer Therapy, September 2012, Taylor & Francis

    Fabian Pitoia

  11. Recombinant Human TSH Versus Thyroid Hormone Withdrawal

    Article • Journal of Nuclear Medicine, August 2012, Society of Nuclear Medicine

    Fabian Pitoia

  12. Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer

    Article • Journal of Thyroid Research, January 2012, Hindawi Publishing Corporation

    Fabian Pitoia

  13. Patients with familial non-medullary thyroid cancer have an outcome similar to that of patients with sporadic papillary thyroid tumors

    Article • Arquivos Brasileiros de Endocrinologia & Metabologia, April 2011, FapUNIFESP (SciELO)

    Fabian Pitoia

  14. Resolution of Cushing's Syndrome and Exacerbation of Autoimmune Thyroiditis

    Article • Thyroid, February 2011, Mary Ann Liebert Inc

    Fabian Pitoia

  15. Metformin Treatment for Small Benign Thyroid Nodules in Patients with Insulin Resistance

    Article • Metabolic Syndrome and Related Disorders, February 2011, Mary Ann Liebert Inc

    Fabian Pitoia

  16. Response to Niepomniszcze and Pitoia

    Article • Thyroid, February 2011, Mary Ann Liebert Inc

    Fabian Pitoia

  17. Differences Between Latin American and American Associations' Thyroid Cancer Guidelines

    Article • Thyroid, April 2010, Mary Ann Liebert Inc

    Fabian Pitoia

  18. Response to Pitoia and Ward

    Article • Thyroid, April 2010, Mary Ann Liebert Inc

    Fabian Pitoia

  19. Development of Gravesʼ Disease Following a Radioiodine Dose for the Shrinkage of a Multinodular Goiter After Using a Novel Protocol

    Article • The Endocrinologist, January 2010, Wolters Kluwer Health

    Fabian Pitoia

  20. Latin American Thyroid Society recommendations for the management of thyroid nodules

    Article • Arquivos Brasileiros de Endocrinologia & Metabologia, December 2009, FapUNIFESP (SciELO)

    Fabian Pitoia

  21. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer

    Article • Arquivos Brasileiros de Endocrinologia & Metabologia, October 2009, FapUNIFESP (SciELO)

    Fabian Pitoia

  22. Increased Prevalence of Insulin Resistance in Patients With Differentiated Thyroid Carcinoma

    Article • Metabolic Syndrome and Related Disorders, August 2009, Mary Ann Liebert Inc

    Fabian Pitoia

  23. Recombinant Human TSH: The Argentinean Experience

    Article • Thyroid, July 2009, Mary Ann Liebert Inc

    Fabian Pitoia

  24. Thyroid Cancer: Does the Size Matter?

    Article • Thyroid, December 2008, Mary Ann Liebert Inc

    Fabian Pitoia

  25. Response to Pitoia and Niepomniszcze

    Article • Thyroid, December 2008, Mary Ann Liebert Inc

    Fabian Pitoia, Elizabeth Pearce

  26. Optimum Recombinant Human Thyrotropin Dose in Patients with Differentiated Thyroid Carcinoma and End-Stage Renal Disease

    Article • Endocrine Practice, November 2008, AACE Corp (American Association of Clinical Endocrinologists)

    Fabian Pitoia

  27. Fatal outcome of a young woman with papillary thyroid carcinoma and graves' disease: possible implication of "cross-signalling" mechanism

    Article • Arquivos Brasileiros de Endocrinologia & Metabologia, October 2008, FapUNIFESP (SciELO)

    Fabian Pitoia

  28. Introducing the Thyroid Gland as Another Victim of the Insulin Resistance Syndrome

    Article • Thyroid, April 2008, Mary Ann Liebert Inc

    Fabian Pitoia

  29. Case Reports: Follicular Carcinoma Presenting as Autonomous Functioning Thyroid Nodule and Containing an Activating Mutation of the TSH Receptor (T620I) and a Mutation of The Ki-RAS (G12C) Genes

    Article • Thyroid, May 2006, Mary Ann Liebert Inc

    Fabian Pitoia

  30. Primary thyroid disorders in endogenous Cushing's syndrome

    Article • European Journal of Endocrinology, September 2002, Bioscientifica

    Fabian Pitoia

  31. Tumour growth after recombinant human TSH

    Article • Clinical Endocrinology, August 2002, Wiley

    Fabian Pitoia

  32. Regulation of Prolactin, GH, and Pit-1 Gene Expression in Anterior Pituitary by Pitx2: An Approach Using Pitx2 Mutants

    Article • Endocrinology, August 2002, Endocrine Society

    Fabian Pitoia

  33. Development of Graves' Hyperthyroidism After Radioiodine Treatment for a Toxic Nodule: Is the Hyperthyroidism Always Triggered by 131 I Therapy?

    Article • Thyroid, October 2001, Mary Ann Liebert Inc

    Fabian Pitoia